Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study to assess the safety, tolerability,
pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in
patients with metastatic or locally advanced colorectal or gastric/gastroesophageal junction
adenocarcinoma